GH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 38 cases where GH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 51 cases where GH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
Following a +5.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where GH advanced for three days, in 241 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 179 of 210 cases where GH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The 10-day RSI Indicator for GH moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 26 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GH as a result. In 63 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for GH turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 33 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
GH moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GH crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-98.112) is normal, around the industry mean (66.046). P/E Ratio (-46.422) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. GH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 79 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
TCMD saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned positive. In 77 of the 98 cases, the stock moved higher in the following days. The odds of a move higher are at 79%.
TCMD moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TCMD crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 70%.
Following a +4.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where TCMD advanced for three days, in 213 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
TCMD broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TCMD entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. TCMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.382) is normal, around the industry mean (2.874). P/E Ratio (21.596) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.290) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (1.458) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
GH | TCMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 85 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 79 | 100 | |
SMR RATING 1..100 | 100 | 65 | |
PRICE GROWTH RATING 1..100 | 36 | 48 | |
P/E GROWTH RATING 1..100 | 54 | 54 | |
SEASONALITY SCORE 1..100 | 90 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GH's Valuation (15) in the Medical Or Nursing Services industry is somewhat better than the same rating for TCMD (73) in the Medical Specialties industry. This means that GH’s stock grew somewhat faster than TCMD’s over the last 12 months.
GH's Profit vs Risk Rating (79) in the Medical Or Nursing Services industry is in the same range as TCMD (100) in the Medical Specialties industry. This means that GH’s stock grew similarly to TCMD’s over the last 12 months.
TCMD's SMR Rating (65) in the Medical Specialties industry is somewhat better than the same rating for GH (100) in the Medical Or Nursing Services industry. This means that TCMD’s stock grew somewhat faster than GH’s over the last 12 months.
GH's Price Growth Rating (36) in the Medical Or Nursing Services industry is in the same range as TCMD (48) in the Medical Specialties industry. This means that GH’s stock grew similarly to TCMD’s over the last 12 months.
GH's P/E Growth Rating (54) in the Medical Or Nursing Services industry is in the same range as TCMD (54) in the Medical Specialties industry. This means that GH’s stock grew similarly to TCMD’s over the last 12 months.
| GH | TCMD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | N/A |
| Stochastic ODDS (%) | 1 day ago 86% | 1 day ago 77% |
| Momentum ODDS (%) | 1 day ago 79% | 1 day ago 79% |
| MACD ODDS (%) | 1 day ago 77% | N/A |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 85% |
| Advances ODDS (%) | 2 days ago 83% | 3 days ago 78% |
| Declines ODDS (%) | 4 days ago 85% | 16 days ago 77% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 79% |
| Aroon ODDS (%) | 1 day ago 85% | 4 days ago 72% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GH’s FA Score shows that 1 FA rating(s) are green while TCMD’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GH’s TA Score shows that 4 TA indicator(s) are bullish while TCMD’s TA Score has 4 bullish TA indicator(s).
GH (@Medical Specialties) experienced а +2.25% price change this week, while TCMD (@Medical/Nursing Services) price change was +1.07% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
GH is expected to report earnings on Nov 05, 2026.
TCMD is expected to report earnings on Nov 02, 2026.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-1.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor indicates that over the last year, GH has been loosely correlated with NTRA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GH jumps, then NTRA could also see price increases.